Lastly, it should be mentioned that none of the epigenetic therapies discussed—such as HDAC inhibitors, miRNA-targeted approaches, or CRISPR/dCas9-based tools—has, to date, received approval for clinical use specifically in atrial fibrillation. Here, HDAC9 is linked to atrial fibrillation.